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Abstract
Anchorage-independent proliferation is a hallmark of oncogenic transformation and is thought to be conducive to
proliferation of cancer cells away from their site of origin. We have previously reported that primary Schwann cells
expressing the SV40 Large T antigen (LT) are not fully transformed in that they maintain a strict requirement for attachment,
requiring a further genetic change, such as oncogenic Ras, to gain anchorage-independence. Using the LT-expressing cells,
we performed a genetic screen for anchorage-independent proliferation and identified Sensory and Motor Neuron Derived
Factor (SMDF), a transmembrane class III isoform of Neuregulin 1. In contrast to oncogenic Ras, SMDF induced enhanced
proliferation in normal primary Schwann cells but did not trigger cellular senescence. In cooperation with LT, SMDF drove
anchorage-independent proliferation, loss of contact inhibition and tumourigenicity. This transforming ability was shared
with membrane-bound class III but not secreted class I isoforms of Neuregulin, indicating a distinct mechanism of action.
Importantly, we show that despite being membrane-bound signalling molecules, class III neuregulins transform via a cell
intrinsic mechanism, as a result of constitutive, elevated levels of ErbB signalling at high cell density and in anchorage-free
conditions. This novel transforming mechanism may provide new targets for cancer therapy.
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Introduction
Most normal mammalian cells require both mitogens and
anchorage signals in order to proliferate, and are sensitive to anti-
proliferative cues from surrounding cells, a process known as
contact inhibition. In contrast, proliferation in the absence of
mitogens, loss of contact inhibition and anchorage-independent
proliferation are thought to be key characteristics of cancer cells
[1] with anchorage-independent proliferation a powerful predictor
of tumourigenic and metastatic potential [2]. Previous studies in
several primary cell types have demonstrated that multiple genetic
changes are required to enable anchorage-independent prolifer-
ation. These cooperative events commonly involve inactivation of
the Rb and p53 tumour suppressor pathways together with
activation of Ras signalling pathways [3].
Primary rat Schwann cells can be passaged indefinitely in
culture while maintaining normal cell-cycle checkpoints [4].
Previous characterisation of the oncogenic pathways required to
transform these cells showed that, as for other cell types,
expression of SV40 Large T antigen (LT), which inactivates the
p53 and Rb pathways, permits the cells to proliferate mitogen-
independently but they retain a strict requirement for attachment
and exhibit contact inhibition of proliferation. However, coex-
pression of oncogenic Ras allows both proliferation in the absence
of anchorage and at high cell densities [5]. Consistent with these
findings, Schwann cell tumours frequently have defects in the p53
and Rb pathways and activation of the Ras pathway, induced for
example by loss of the NF1 gene [6,7].
To identify genes capable of inducing anchorage-independent
proliferation and thus potential new targets for cancer therapy, we
established a cDNA retroviral screen in LT-expressing Schwann
cells. From this screen, we isolated the SMDF isoform of
Neuregulin 1 (NRG1). Neuregulins are a large family of EGF-
like ligands involved in cell-cell communication in many different
cell types [8,9]. The complexity of NRG1 signalling is partly the
result of a large number of alternatively-spliced forms that signal in
distinct ways [10]. The class I and II forms of NRG1 act as classic
soluble factors whereas class III isoforms, of which SMDF is a
member, remain anchored to the membrane and signal to
neighbouring cells in a juxtacrine manner. Class III members of
the NRG1 family play a pivotal role in the life of a Schwann cell.
Expressed by axons, they signal to Schwann cells by direct contact,
promoting proliferation of the progenitor cells during development
then differentiation and myelination at later stages [11,12,13,14,15].
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11774Here we find that class III members of this family - including SMDF,
but not class I secreted forms - when expressed directly by Schwann
cells promote oncogenic transformation. This cell-intrinsic behaviour
appears to be the result of constitutive neuregulin signalling at high
density and in the absence of anchorage. The oncogenic activity of
class III isoforms of neuregulin identifies a further role for this family
of signalling molecules in the development of cancer.
Results
A screen for anchorage-independent proliferation
Schwann cells expressing LT (NSLT) are strictly dependent on
attachment signals for proliferation, yet only require a single
additional change, such as oncogenic Ras expression, to proliferate
anchorage-independently [5]. Moreover, as these cells have an
extremely low rate of spontaneous transformation they are an ideal
cell system for a screen aimed at the isolation of novel genes
promoting anchorage-independent proliferation. For the screen,
we infected 20 million NSLT with either a retroviral cDNA
expression library derived from human fetal brain or the same
parental vector expressing GFP as a negative control. We chose
this library since overexpression is a common method of oncogene
activation in cancer cells and fetal brain is likely to contain cells
with stem-like proliferative potential. After infection, cells were
plated in soft agar suspension and screened for colony formation.
As expected, no colonies formed in GFP cells. In contrast, from
cells infected with the library, we retrieved 4 colonies. Importantly,
cells dissociated and expanded from all isolated colonies
maintained anchorage-independent proliferation when replated
in soft agar (not shown).
From the 4 colonies, 7 inserts were amplified by PCR. These
were sequenced and re-cloned into the original retroviral
vector. Of these, only 2 induced anchorage-independent
p r o l i f e r a t i o nw h e nr e i n t r o d u ced into NSLT (Figure 1A). One
of these inserts contained the protein kinase domain of c-Raf1.
c-Raf1 is an immediate downstream target of the Ras pathway
with known transforming activity [16] and therefore confirmed
the validity of the screen and suggested that in Schwann cells,
Ras acts through Raf to induce anchorage independent
proliferation.
NRG1 SMDF promotes oncogenic transformation
The other insert isolated in the screen encoded the full length
SMDF isoform of NRG1. SMDF (NRG1 III-b3) is a transmem-
brane member of the NRG family of signalling molecules [10,17]
and is similar to the cleaved form of the more commonly expressed
Figure 1. A screen for genes promoting anchorage-independent proliferation identifies SMDF. (A) Schematic of screening strategy and
phase-contrast images of colonies formed after 3 weeks in soft agar from which the indicated inserts were isolated. Raf1 pkd = protein kinase
domain of Raf1. (B) Schematic of the structure of the different forms of Neuregulin1 investigated in our study. CRD= cysteine-rich domain. TM=
transmembrane region. (C) NSLT infected with Ras, SMDF or control vector were plated in suspension in soft agar and colonies stained after 3 weeks.
doi:10.1371/journal.pone.0011774.g001
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not GFP infected NSLT formed colonies in suspension with a
similar efficiency to Ras infected NSLT indicating that SMDF is
contributing to transformation directly and not through additional
mutation (Figure 1C). Loss of contact inhibition is a distinct
property of transformed cells, so we tested the ability of SMDF
expression to stimulate proliferation at confluence. We retrovirally
infected and selected pools of NSLT cells with SMDF, Ras or
empty vector (Figure 2A), seeded the cells at sub-confluency and
then counted cells at different times after plating (Figure 2B).
NSLT infected with empty vector slowed their proliferation rate
around confluence whereas SMDF-expressing cells, like those
expressing Ras, kept proliferating reaching a higher cell density.
To assess whether SMDF infected NSLT were tumourigenic we
inoculated LXSN, SMDF or Ras infected NSLT into the flanks of
nude mice. Strikingly, in less than 2 weeks, all SMDF (10/10) and
Ras (4/4) inoculations resulted in tumours with comparable
growth rates (Figure 2C). In contrast, no NSLT infected with
empty vector LXSN (0/10) gave rise to tumours. To confirm that
the tumours arose from LT Schwann cells expressing SMDF, we
dissociated and cultured cells from 3 SMDF tumours. Immuno-
fluorescence analysis showed that the majority of these cells
retained expression of the Schwann cell marker S100 and LT
antigen (Figure 2D) confirming that the tumours were derived
from NSLT. Moreover, SMDF expression was maintained
(Figure 2A). As expected, these cells also maintained the capacity
to proliferate in suspension (not shown). Together these results
show that SMDF cooperates with LT to induce full oncogenic
transformation.
SMDF expression confers a proliferative advantage to
normal Schwann cells
Oncogenic Ras is transforming in the presence of additional
genetic changes. When expressed alone in primary cells however,
oncogenic Ras induces premature senescence, a putative tumour
suppressor mechanism to protect from uncontrolled proliferation
[18]. To address the effects of SMDF expression in normal cells,
we infected primary Schwann cells with Ras (NSRas), SMDF
(NSSMDF) or an empty LXSN vector control (NSLXSN) and
isolated pools of neomycin resistant cells. Following drug selection,
a clear phenotypic change was observed in both the NSRas and
NSSMDF cells. NSRas cells developed a classical senescent
phenotype with large multinucleated cells that stained positively
for the senescence marker b-galactosidase at pH 6.0 (Figure 2E).
Moreover these cells could not be expanded in culture unlike
control cells (Figure 2F). In contrast, NSSMDF cells developed a
refractile appearance, proliferated more rapidly than control cells
and did not undergo premature senescence as judged by staining
negatively for b-galactosidase and by readily expanding in culture
(Figure 2E and 2F). It has previously been shown that the ERK
signalling pathway mediates Ras-induced senescence [19,20,21].
Consistent with this, Ras expression induced higher levels of P-
ERK compared to that seen in SMDF expressing cells (Figure 2F).
NSSMDF cells however, had lost certain proliferative controls in
that they continued to proliferate at confluency, reaching a higher
density than control cells (Figure 2G). Together these results show
that SMDF expression, unlike oncogenic Ras, fails to induce
senescence but instead promotes deregulated proliferation of
normal primary cells. These cells are not fully transformed
however, as they are unable to form colonies in soft agar (not
shown). Nevertheless, the fact that overexpression of SMDF does
not induce premature senescence could make it a favourable early
event in tumourigenesis.
SMDF transforms via ErbB receptor signalling
NRG1 isoforms share an EGF domain through which they bind
to and activate the ErbB family of receptors [10]. In Schwann
cells, it has been shown that ErbB-2/ErbB-3 receptor heterodi-
mers mediate neuregulin signalling as Schwann cells do not
express ErbB-1 and ErbB-4 [14,22]. Increased levels of ErbB-2
receptor phosphorylation were detectable in NSLTSMDF cells
and the SMDF expressing cells isolated from tumours (SMDFT)
when compared to control cells (Figure 3A) indicating that
receptor signalling was activated in these cells. Total ErbB-2 levels
appeared somewhat lower in SMDF expressing cells than in
LXSN infected cells consistent with previously reported ligand-
induced degradation of the receptor [23]. To address whether
ErbB-2/ErbB-3 signalling was responsible for SMDF transforming
activity we took two distinct approaches. First, we determined the
effects of ErbB inhibitors on SMDF induced transformation. Using
the cell-permeable, ErbB-specific inhibitor 4557W [24] we found
that the proliferation at confluency of SMDF infected cells and
cells dissociated from SMDF tumours was selectively blocked by
the inhibitor in a dose-dependent manner (Figure 3B). As
expected, the levels of phosphorylated ErbB-2 receptor were
strongly downregulated in these cells when treated with inhibitor
(Figure 3A). In contrast, no significant differences in the number
and morphology of cells were observed in the presence of the
inhibitor for control cells and importantly in Ras infected NSLT.
To confirm these findings, we repeated the cell density
experiments with two separate ErbB-2 inhibitors and got similar
results (Figure S1). To address whether ErbB-2/-3 signalling was
responsible for the ability of SMDF to induce anchorage-
independent proliferation, we added ErbB inhibitor to the soft
agar assays and found that while it had no effect on the ability of
Ras expressing NSLT cells to form colonies it completely blocked
NSLTSMDF colony formation (Figure 3C). As a second
approach, we made a point mutation in the SMDF EGF domain,
which has previously been shown to disrupt binding to ErbB
receptors (here referred to as SMDF*) [25]. The expression of
SMDF* in NSLT cells failed to induce proliferation at confluence
(Figure 3B) and anchorage independent proliferation (Figure 3D),
despite comparable levels of expression (Figure 3A). Together
these results show that SMDF exerts its transforming activity
through ErbB-2/ErbB-3 receptors.
ErbB-2/ErbB-3 signalling is known to stimulate proliferation
through the ERK and PI3-K signalling pathways [22]. To
determine the role of these signalling pathways we treated
preconfluent NSLT and NSLTSMDF with the MEK inhibitor
U0126 and the PI3-K inhibitor LY 294002. Both inhibitors
blocked the ability of the SMDF expressing cells to proliferate at
confluency (Figure 3E). Moreover, both inhibitors blocked the
ability of NSLTSMDF cells to form colonies in soft agar
(Figure 3C) indicating that both of these signalling pathways are
important for the transforming activity of SMDF. In contrast, the
proliferation of Ras-expressing cells was much less sensitive to PI3-
K inhibition at confluency although they also required this
pathway to proliferate in soft agar. However, when we analysed
the levels of activation of these signalling pathways we detected a
dramatic activation of signalling by the PI3-K pathway as
determined by high levels of p-AKT in the SMDF-expressing
cells but could not reproducibly detect any increase in the levels of
phosphorylated ERK (Figure 3E), although we could detect
elevated levels in the NSSMDF cells (Figure 2F). These results are
consistent with the reported strong signalling to the PI3-K
pathway by the ErbB-2/-3 heterodimer yet indicate that signalling
through both pathways is required for transformation [22].
SMDF Induces Transformation
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signals and proliferate in the absence of anchorage. In normal
cells, both of these cell-cycle checkpoints are reported to involve
mechanisms by which mitogens can no longer activate intracel-
lular signalling pathways [26,27]. Consistent with these findings,
the addition of mitogens to NSLT cells, at increasing cell densities
and in the absence of anchorage, was unable to stimulate PI3-K
signalling. In contrast, NSLTSMDF cells maintained high PI3-K
signalling both at high density and in the absence of anchorage
(Figure 3F and G).
NRG1 class III but not class I isoforms are transforming
NRG1 class I isoforms act as classic soluble EGF-like factors
whereas class III isoforms signal to neighbouring cells in a
juxtacrine fashion. SMDF belongs to class III and shares with
other members of this class a cysteine-rich domain (CRD) that
anchors the protein to the cell surface [10]. To address whether
the transforming activity was restricted to SMDF, we expressed
two other well-characterised NRG1 isoforms in NSLT cells both
of which are highly expressed in the PNS, from class I (I-b1a) or
class III (III-b1a) [12] (Figure 1B). Detailed characterisation of
these isoforms has shown that whilst the EGF-containing domain
of NRGI I-b1a is efficiently shed from cells, including Schwann
cells, the majority of NRG1 III-b1a remains at the cell surface
[28]. RT-PCR analysis showed that the two isoforms were
expressed at comparable levels in the NSLT cells (Figure 4A) and
immunocytochemistry detected similar levels of protein within the
cells (Figure 4B). The NRG1 I-b1a and NRG1 III-b1a expressing
cells exhibited a similar transformed phenotype with cells more
spindly and refractile than vector control cells (Figure 4C).
However, only the class III isoform efficiently induced colony
formation in NSLT and was capable of overcoming contact
inhibition to allow cell proliferation at high densities (Figure 4C
and 4D). Consistent with these results, only the class III isoforms
stimulated high levels of PI3-K signalling at high cell densities
(Figure 4E). Together these results indicate a specific role for class
III as opposed to class I NRG1 isoforms in promoting oncogenic
transformation.
SMDF transforms NSLT cells via a cell-intrinsic
mechanism
A distinction between the class I and class III isoforms is that the
class I molecules act as soluble factors whereas the class III
molecules tend to signal by direct cell-cell contact. However, it has
been reported that the transmembrane class III NRG1 isoforms
can also be processed and released as soluble factors, albeit at low
efficiency [8,29]. To determine whether class III NRG1 isoforms
exert their transforming activity as secreted, soluble factors, we
asked whether the addition of conditioned medium from
NSLTSMDF or high levels of recombinant soluble SMDF could
transform NSLT cells. As shown in Figure 5A, the daily addition
of either conditioned medium or high levels of soluble SMDF was
unable to stimulate proliferation at high density. Similar results
were obtained by adding the recombinant extracellular domain of
NRG1 I-b1a or the recombinant EGF domain of NRG1 I-b1a
(not shown). Moreover, the addition of recombinant factors to
NSLTLXSN cells in soft agar was unable to promote colony
formation (not shown). This was despite the ability of both
recombinant SMDF and recombinant NRG1 I-b1a to stimulate
DNA synthesis in quiescent Schwann cells (Figure S1C).
Consistent with these results and previous studies [28], we were
only able to detect mitogenic activity in conditioned medium from
NRG1 I-b1a- expressing cells, which correlated with activation of
the ErbB-2/B-3 receptor complex in the stimulated Schwann cells
(Figure 5B). Together these results suggest that SMDF is not acting
as a soluble factor to mediate its transforming effect. SMDF could
therefore signal in a juxtacrine manner to neighbouring cells, or
drive a cell-intrinsic mechanism inducing proliferation only in
SMDF-expressing cells. To distinguish between these possibilities,
we used a vector driving the expression of GFP together with
SMDF. We set up a series of experiments using mixed populations
of cells, GFP-positive expressing an empty vector, SMDF or Ras,
and GFP-negative controls. We then assessed the percentage of
GFP-positive cells at different times after plating at high density -
conditions in which control cells fail to proliferate. If the GFP-
positive cells overexpressing SMDF proliferate faster than the
GFP-negative control cells, we would expect the percentage of
GFP-positive cells to increase over time. Figure 5C shows that
when approximately 1 in 10 of the cells were initially GFP-positive
and coexpressing SMDF or Ras, the percentage of GFP-positive
cells increased with time until, by 7 days, the GFP cells constituted
greater than 40% of the cell population. Similar results were
obtained starting from a 1:1 ratio of GFP positive and GFP-
negative cells (not shown). The proliferation rate of GFP negative
cells was comparable in all samples tested (Figure 5C and not
shown). These results indicate that SMDF transforms cells by a cell
intrinsic mechanism.
Discussion
We report here a retroviral cDNA screen for genes promoting
anchorage-independent proliferation in a mammalian cell model
system. Rat Schwann cells expressing SV40LT proliferate in the
absence of mitogens but retain other cell-cycle checkpoints such as
anchorage dependence and contact inhibition of proliferation.
However, they require only one additional genetic lesion (for
example, oncogenic Ras) for complete neoplastic transformation
[5]. Despite the loss of p53 and Rb checkpoints, Schwann cells
expressing LT are genetically stable, with an extremely low rate of
spontaneous transformation [30]. These cells are thus a useful
mammalian model system to identify potential oncogenes. The
validity of this approach was confirmed by the isolation of an insert
expressing the protein kinase domain of a known oncogene, RAF1,
Figure 2. SMDF promotes oncogenic transformation. (A) Western blot analysis of total lysates from NSLT cells selected to express human
SMDF or control vector (LXSN). SMDF(T) are derived from tumours, induced by injecting NSLTSMDF cells into nude mice. (B) Cell counts 2/+ S.D.
following seeding of 10
5 NSLT cells per well expressing SMDF, Ras or control vector (LXSN) in triplicate in 6 well plates. Medium was changed daily.
Experiment shown is representative of 3 separate experiments. Representative phase-contrast images of the cells at high density. (C) NSLT cells
expressing SMDF, Ras or control vector (LXSN) were injected into the flanks of nude mice. Ras cells were only injected into a single flank. Picture
shows examples of tumours formed (SMDF (left), Ras (right)) and the graph shows the average growth of the tumours 2/+ S.D.. (D) Representative
images of cells dissociated from NSLTSMDF derived tumours stained for LT (upper panel) or the Schwann cell marker, S100 (lower panel). Primary
Schwann cells (NS) were infected with retroviral vectors expressing SMDF, Ras or the control vector (LXSN) and selected in G418. One week following
selection, the cultures were fixed and stained for the senescence marker b-Galactosidase at pH 6 (E) or seeded in triplicate and counted for four
passages (F). Western blot shows p-ERK levels in lysates prepared from NS cells expressing Ras, SMDF or control vector (LXSN) six days after infection.
(G) 2610
5 NS cells infected with SMDF or control vector (LXSN) were plated in triplicate in 6 well dishes and counted at the indicated days. Medium
was changed daily. Error bars show 2/+ S.D..
doi:10.1371/journal.pone.0011774.g002
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PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11774Figure 3. SMDF transforms via ErbB receptor signalling. (A) Western blot analysis of indicated proteins in NSLT cells expressing SMDF, SMDF*
(point mutant incapable of binding ErbB receptors) or control vector (LXSN), and SMDF(T) cells derived from SMDF tumours in the absence or presence of
the ErbB-2 inhibitor, 4557W (40 nM). (B) Cell countsoftriplicatewells in the presenceor absenceof theindicated concentrations of 4557W 2/+ S.D.. Figure
is representative of 3 independent experiments. (C) Number of colonies formed in soft agar assays of NSLT cells expressing SMDF, Ras or control vector
LXSN in the absence or presence of the indicated inhibitors. U0126 (UO), LY294002 (LY) and the ErbB inhibitor (ErbBI). 12 fields were counted per well with
the results shown as average/well 2/+ S.D.. Results are representative of two separate experiments (D) Soft agar assays of NSLT cells infected with SMDF,
SMDF* or control vector (E) 10
5 NSLT cells expressing SMDF, Ras or control vector (LXSN) were seeded in triplicate into 6 well dishes and counted at 72 h.
TheinhibitorsU0126(20 mM), LY294002 (20 mM)orcontrolvehiclewereaddedwhereindicatedat36 hours.WesternblotanalysisoftotallysatesfromNSLT
cellsexpressingSMDForcontrolvector(LXSN).(F)WesternblotanalysisoftotallysatesfromNSLTcellsexpressingSMDForcontrolvector(LXSN)collected 3
(preconfluent), 6 and 9 days after seeding. Plates were medium changed daily. (G) Western blot analysis of total lysates from NSLT cells expressing SMDF,
Ras or control vector (LXSN) in attached (att) or anchorage-independent conditions (sus).
doi:10.1371/journal.pone.0011774.g003
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11774Figure 4. Transmembrane Class III Neuregulin 1 isoforms are transforming. (A) QPCR analysis of the mRNA levels and (B) immunostaining
of NRG1 I-b1a and NRG1 III-b1a infected NSLT cells. (C) Phase contrast micrographs of NSLT infected with NRG1 I-b1a, NRG1 III-b1a or control vector
(LXSN). The same cells together with SMDF and Ras- expressing cells were plated into soft agar and colonies stained after 3 weeks (C) or plated in
triplicate and counted at indicated times (D) (Results shown are mean 2/+ S.D.). (E) Western analysis of total lysates prepared from confluent LT cells
expressing NRG1 I-b1a, NRG1 III-b1a, SMDF or control vector.
doi:10.1371/journal.pone.0011774.g004
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of a candidate oncogene, SMDF, a transmembrane isoform of
NRG1. It is likely that this screening protocol would be useful for
identifying further oncogenes using alternative libraries and/or
larger screens.
In Schwann cells expressing LT, we found that SMDF was
sufficient to confer full cellular transformation: similarly to
oncogenic Ras expression, the expressing cells grew to higher
densities, proliferated in the absence of anchorage and formed
tumours in immuno-compromised mice. However, when ex-
Figure 5. SMDF transforms by a cell-intrinsic mechanism. (A) Cell counts from triplicate wells of NSLT cells treated daily with conditioned
medium from SMDF infected cells or recombinant SMDF (200 ng/ml). SMDF-infected NSLT cells were used as a positive control. Results shown are
mean 2/+ S.D. (B) Conditioned medium collected from confluent Schwann cells as indicated was used to stimulate Schwann cells in defined medium.
Upper graphs shows BrdU incorporation of the stimulated cells (2/+ S.D.). Lower panel shows activation of the ErbB-2/-3 receptor as measured by
levels of (P) ErbB-3. (C) NSLT cells were infected with SMDF, Ras or control vector GFP. The GFP-expressing cells were then mixed at a 1:10 ratio with
uninfected cells and plated in triplicate at sub-confluent density. At the times shown, the cells were trypsinised and reseeded and the percentage
GFP-expression counted. Representative fluorescent and phase-contrast images are shown in the right hand panel (day 7).
doi:10.1371/journal.pone.0011774.g005
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expression had distinct effects, in that oncogenic Ras induced
cellular senescence, a checkpoint response thought to protect
against the development of cancer, whereas SMDF expression
conferred a proliferative advantage. It is known that cellular
senescence induced by oncogenic Ras is mainly mediated by
excessive signalling through the ERK signalling path-
way[19,20,21]. Consistent with this, lower levels of ERK signalling
was detected in SMDF-expressing cells compared to Ras-
expressing cells. Also indicative of differential signalling, we found
that confluent SMDF expressing LT cells were sensitive to
inhibition of the PI3-K pathway whereas Ras-expressing cells
were relatively unaffected. However, both the PI3-K pathways and
the ERK pathways were required for SMDF-induced transfor-
mation. The observation that SMDF expression gave a prolifer-
ative advantage to primary Schwann cells without triggering the
cellular ‘‘damage’’ response might indicate that SMDF expression
could be a favourable early event in Schwann cell tumourigenesis.
Interestingly, whilst oncogenic Ras is rarely found in Schwann cell
derived tumours, SMDF and related family members appear to be
expressed in a number of these tumour types [31,32,33].
SMDF is a member of a large family of secreted and
membrane-bound factors produced by alternative splicing of the
NRG1 gene. Despite their differences, what is common to the
isoforms is that they signal, via an EGF domain, to activate the
ErbB family of receptors. Consistent with this known mechanism
of action, we found that SMDF-transforming activity requires
signalling through the ErbB-2 receptor. However, despite the
ability of all NRG isoforms to activate this receptor, we found that
not all isoforms were equally transforming. In particular, a
secreted class I isoform was inactive in our assays, even though
these cells exhibited a transformed morphological phenotype. A
property unique to the class III isoforms is that they normally
signal as membrane-bound ligands suggesting that this may be
important for their transforming activity. Consistent with this idea,
adding high levels of a recombinant soluble form of SMDF was
unable to confer any transforming ability. Interestingly, in line
with our findings, it has been shown that transmembrane (class III)
isoforms of NRG1 are more commonly over-represented than
soluble (class I) forms in Schwann cell tumours, suggesting that
differences between the isoforms may be relevant for tumour
formation in vivo [32,33,34].
Class III isoforms of NRG1 normally signal in a juxtacrine
fashion to neighbouring cells however, we have found that SMDF
transforms by an intrinsic mechanism. It is not clear whether
membrane-bound SMDF activates ErbB-2/ErbB-3 at the plasma
membrane or whether signalling takes place on intracellular
vesicles, as we have not been able to detect the activated receptor
by immunostaining (unpublished observations). However, what is
clear is that when SMDF is expressed in the same cell as its
receptor, it leads to constitutive activation of the ErbB-2 receptor
and sustained activation of downstream signalling pathways.
Moreover, the signalling is maintained at high cell density and
in the absence of anchorage, when normal mitogenic signalling is
suppressed. This suggests the autocrine loop established by co-
expression of the membrane-bound ligand and its receptor results
in sustained signalling, which is not subject to the regulatory
mechanisms that suppress signalling when cells get too dense or
lose anchorage. Although we have found that class III isoforms of
NRG1 are potent in their transforming activities, our work does
not rule out the possibility that other isoforms of NRG1 may also
contribute to tumourigenesis. Indeed class II isoforms of NRG1
have also found to be expressed in Schwann cell derived tumours
[32,34] and in a transgenic mouse model, expression of a class II
isoform in Schwann cells led to mice developing hyperplasia with
60% progressing to develop tumours that resembled human
malignant peripheral nerve sheath tumours [35]. Moreover, class I
isoforms may also be transforming if expressed at higher levels.
Our results do however, indicate a potency of the class III isoforms
and a distinct mechanism of action, which prompts further study.
We have found that class III isoforms transform by the
establishment of a cell-intrinsic autocrine loop. Intriguingly, a
recent study demonstrates that SMDF can also contribute to
tumourigenesis by acting in a juxtacrine fashion. In this study, the
authors constructed a transgenic mouse, which specifically
expressed SMDF in postnatal neurons [36]. This resulted in
Schwann cell hyperplasia and predisposed mice to Schwann cell-
derived tumours. Thus, NRG1 class III isoforms appear to be able
to promote both cell autonomous and non- cell autonomous
oncogenic transformation. It will be of great interest to determine
both the role of these molecules in human tumourigenesis and
their mechanism of action.
Materials and Methods
Retroviral constructs
A retroviral cDNA library from human fetal brain (Stratagene
Viraport 973221) was expanded and prepared for transfection
according to the manufacturer’s instructions. The library vector
backbone pFB containing a GFP insert (pFB-GFP, Stratagene) was
used as a negative control for the screen. The SMDF cDNA
identified in the screen was further subcloned into retroviral
vectors LXSN (Clontech) and GFP containing Pinco (kind gift
from Piergiuseppe Pelicci’s laboratory). The NRG1 I-b1a and III-
b1a isoforms were a kind gift from Doug Falls and Carla Taveggia
and were subcloned into LXSN [28].
Cell culture and retroviral transduction
Schwann cells isolated from the sciatic nerves of 7-day-old rats
were purified and cultured as previously described [4]. All
retroviral infections were performed using viral supernatants
prepared from Phoenix 393T producer cells transiently trans-
fected with the library/vector of interest for 48 h using
Lipofectamine plus (Invitrogen). The cells to be infected were
plated the previous day (2.7610
4 cells/cm
2) and retroviral
transduction was performed by incubation for 3 hours at 37uC/
5% CO2 in the presence of filtered viral supernatant containing
8 mg/ml polybrene. Following infection the medium was changed
and cells were left to proliferate for 48 h before drug selection or
seeding into soft agar for the screen. Schwann cells stably
expressing SV40 Large T antigen (NSLT) were obtained by
pooling and expanding puromycin-resistant cells (0.5 mg/ml) one
week after infection with pBabe-puro-SV40 (kind gift of James
DeCaprio). Primary Schwann cells (NS) were infected with
LXSN, LXSN-SMDF or LXSN-Ras and selected in G418
(0.6 mg/ml) for 1 week. Recombinant soluble human SMDF
(378-SM), and the extracellular (377-HB) and EGF domains (396-
HB) of human NRG1 I-b1a were purchased from R&D Systems
and used at the indicated concentrations. To collect conditioned
medium, indicated cells were cultured to confluency, washed
twice in DMEM and cultured for a further 24 hours in defined
medium (DMEM containing 100 mg/ml transferrin, 100 mg/ml
BSA, 60 ng/ml progesterone, 50 ng/ml thyroxine, 50 ng/ml tri-
iodothyrine, 16 mg/ml putrescine and 40 ng/ml selenium). The
medium was then used to stimulate sub-confluent Schwann cells
in defined medium. BrdU incorporation was performed as
previously described [30].
SMDF Induces Transformation
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11774Screen for anchorage-independent proliferation
Low passage NSLT cells were infected with the retroviral cDNA
library48 hbeforeseedingintosoftagar(5610
5cellsper15 cmdish),
which consisted of 0.45% Seaplaque agarose in normal culture
medium. Soft agar cultures were incubated at 37uC/5% CO2 for 3
weeks and fed weekly with fresh medium. Colonies were isolated
using a pipette tip and briefly expanded in adherent cultures before
isolation of genomic DNA using the DNAeasy kit (Qiagen). Primers
pFB 59 59-GGCTGCCGACCCCGGGGGTGG-39 and pFB 39 59-
CGAACCCCAGAGTCCCGCTCA-39 were used to amplify inte-
grated viral DNA and the resulting amplicons were cloned directly
into the Zero Blunt vector (Invitrogen) before sequencing with pFB
and T7 primers. All inserts isolated were further subcloned into the
pFB vector for further validation of their capacity to transform.
Transformation Assays
To measure anchorage independent proliferation, cells were
seeded in soft agar (as described above) at 3610
3 cells/well in 6
well dishes in triplicate. Resulting colonies were visualised by
staining with MTT (Calbiochem). For the inhibitor studies, the
inhibitors U0126 (20 mM), LY294002 (20 mM) and ErbBI
(N-(4-((3-Chloro-4-fluorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)
2-butynamide (Calbiochem)) (20 mM) were added in 1 ml of
medium at 5X the final concentration to the 4 ml agar wells. To
assess the ability of cells to proliferate at confluence, the indicated
number of cells/well were seeded in triplicate in 6 well dishes. Then
at indicated time points, cells were trypsinised and counted using a
Beckman Coulter counter. In mixed population experiments GFP
positive cells were counted using a fluorescent microscope and the
mean of 10 fields used to calculate the percentage. In vivo
tumourigenesis assays were performed in CD1 nude mice (Charles
River) as previously described [37]. Briefly, 2.5610
6 cells were
injected subcutaneously into each flank of the animal. The animals
were then monitored and sacrificed either when tumours reached
10 mm diameter or after a maximum of 35 days. Representative
tumours were collected and cells dissociated with trypsin and
expanded in culture. The senescence marker, SA-bGal was detected
in NS cells as previously described [4], 1 week following retroviral
infection.
Ethics statement: All animal work has been conducted
according to relevant national (Home Office Guidelines) and
international guidelines and was approved by the University
College London ethics committee.
RT-PCR
Total RNA was extracted with the RNeasyPlusMinikit (Qiagen)
and 1 mg of RNA reverse transcribed using SuperScriptII Reverse
Transcriptase (Invitrogen). Pan-Neuregulin primers 59-GGCCTAC-
TGCAAAACCAAGA-39 and 59-TGATGGGCTGTGGAAGT-
GTA-39 were used to detect expression of Nrg1 isoforms and using
the DyNAmo SYBRGreen qPCRKit (NewEngland Biolabs) and
Opticon2 DNAengine (MJResearch) and relative expression values
were obtained by normalizing to GAPDH 59-TGCACCAC-
CAACTGCTTAG-39 and 59-GGATGCAGGGATGATGTTC-39.
Antibodies, Western Blotting and Immunofluorescence
The following antibodies were used for western blotting: b-
tubulin (Sigma T-4026), phosphotyrosine Clone PT-66 (Sigma),
Total ErbB-2 C18 (Santa Cruz), (P)AKT (ser 473) (Cell
Signalling), AKT (H-136 Santa Cruz), (P)ERK (Sigma M8159),
ERK (Sigma M5670), human SMDF AF378 (R&D) ErbB3 and
(P)ErbB-3 (Cell Signalling). To analyse protein expression levels in
cells in suspension, cells were seeded into methylcellulose for
24 hours, then retrieved by centrifugation at 4uC and lysed as
previously described [30]. Cells dissociated from tumours were
seeded on coverslips and stained for LT (PAB419) or S100b
(DAKO). NRG1 isoform expression was detected using an
antibody to the common intracellular domain (SC348 Santa
Cruz).
Supporting Information
Figure S1 Cell counts of triplicate wells seeded at high density
with NSLT cells expressing SMDF, Ras or control vector (LXSN)
in the presence or absence of the ErbB-2 inhibitors (A) ErbBI (N-
(4-((3-Chloro-4-fluorophenyl)amino)pyrido[3,4-d]pyrimidin-6-
yl)2-butynamide at 20 mM (B) ErbB2 inhibitor (4-(3-Phenoxyphe-
nyl)-5-cyano-2H-1,2,3-triazole) at 30 mM 2/+ S.D.. DMSO was
added as control solvent. (C) Recombinant SMDF (200 ng/ml) or
recombinant Nrg1 I-b1a (40 ng/ml) was added to quiescent
Schwann cells in defined medium in the presence of IGF1 (20 ng/
ml). BrdU was added for 8 hours, 18 hours after stimulation.
Results shown are mean of triplicate wells (2/+ S.D.).
Found at: doi:10.1371/journal.pone.0011774.s001 (0.25 MB TIF)
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